Circio Holding ASA (OSE:CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy and cancer vaccines, revealed on Wednesday that it has terminated the exclusive TG01 KRAS cancer vaccine licence option agreement with its Chinese partner IOVaxis Therapeutics in Greater China and Singapore due to non-payment.
Despite previously granting a payment extension, Circio terminated the agreement as IOVaxis failed to make the agreed initial payment of USD300,000.
Dr Erik Digman Wiklund, Circio's CEO, stated that the three collaborative clinical studies in the United States and European Union are proceeding unaffected.
Circio will now explore alternative partnerships for TG01 in China, leaving room for potential reactivation of discussions with IOVaxis if financial obligations are met.
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Oxford BioDynamics announces distribution agreement with Regina Maria for EpiSwitch tests in Romania
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
Novartis to acquire Anthos Therapeutics in USD925m deal to expand cardiovascular pipeline
Hoth Therapeutics and OnTargetx R&D partner on cancer research
CStone Pharmaceuticals' Cejemly included in ESMO NSCLC Living Guideline
TransCode Therapeutics enrols three patients in Cohort 3 of TTX-MC138 Phase 1 clinical trial
Biohit partners with Restalyst to enhance early gastric cancer detection
Henlius's serplulimab approved in Europe for Extensive-Stage Small Cell Lung Cancer
Adicet Bio secures FDA Fast Track Designation for ADI-001 to treat refractory SLE
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Oxford BioDynamics reports high accuracy for blood-based colorectal cancer test
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma
AstraZeneca secures EU recommendation for Imfinzi in limited-stage small cell lung cancer